Opens in a new tab

Insulet v EOFLOW (CFI, 22 November 2024)

Date22 November 2024
CourtCFI
DivisionMilan (IT) Central Division- Section
Type of actionApplication for provisional measures
Registry referenceACT_39640/2024 · ORD_56716/2024
PartiesInsulet Corporation v. EOFLOW Co., Ltd.

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By order of 22 November 2024 (UPC_CFI_380/2024), made after the hearing of 16 October 2024, the Milan Central Division (panel presided over by A. Postiglione) dismissed Insulet Corporation’s application for provisional measures against EOFLOW Co., Ltd. based on the unitary patent EP 4 201 327 (fluid delivery device, insulin pump). The division addressed validity first and found it unlikely that claim 1 is novel over US 2009/0124994, that doubt was enough to refuse the measure, without any examination of infringement. The order also refused to admit, in provisional proceedings, late auxiliary requests amending the claims.

Facts and procedure

Insulet, the proprietor (a divisional in the WO 2013/149186 family, grant published on 19 June 2024), targets EOFLOW’s EOPatch pump, distributed in Europe by Menarini. Its ex parte application, filed on 3 July 2024, was refused on 8 July 2024, and the proceedings continued inter partes. Joinder with the parallel proceedings against Menarini before the Milan Local Division was refused on 4 September 2024, and Menarini’s application to intervene was rejected on 1 October 2024. EOFLOW argued lack of novelty and inventive step over US 2009/0124994 (Roe) and WO 2010/055504 (Yodfat) and brought a revocation action before the same division. Insulet filed four auxiliary requests on 27 August and 16 September 2024.

The applicable law

Provisional measures fall under Art. 62 UPCA and Rule 211 RoP: under Rule 211.2, a sufficient degree of certainty is lacking if it is more likely than not that the patent is invalid. The claim is construed under Art. 69 EPC and its Protocol, the claim being the starting point and the description and drawings explanatory aids (Court of Appeal, 26 February and 13 May 2024). Amendment of the patent falls under Rule 30, amendment of pleadings under Rule 263.

Question

May the proprietor defend its patent in provisional proceedings with late auxiliary requests, and do serious doubts on novelty stand in the way of provisional measures without any examination of infringement?

Decision

On the auxiliary requests, Rule 263 concerns pleadings only. Substantial changes to the claims fall under Rule 30. Even treated as amendments of pleadings, they could have been made earlier with reasonable diligence, having been formalised some three weeks after being raised informally. The division added that admitting patent amendments in provisional proceedings would give the proprietor an unreasonable procedural advantage and turn the summary procedure into a condensed version of the merits.

On validity, feature 4.5.1 does not require the nut to pass entirely through the clutch. Mapping claim 1 onto the figures of Roe, the division rejected Insulet’s objection that the disclosure was unworkable: the shaft is supported only in the operational phase, and the keyhole relates almost exclusively to another embodiment. Claim 1 is therefore unlikely to be novel. Given the harm an injunction would cause the defendant and the revocation action already pending, the doubts on validity prevent the measure. The application and ancillary requests were dismissed. Insulet bears the costs (Art. 69 UPCA, Rule 118.5), the value in dispute was set at EUR 2,500,000 and the ceiling for recoverable representation costs at EUR 400,000.

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Arts. 47, 62 and 69
Rules of Procedure
Rules 30, 118.5, 206, 211, 263 and 333
European Patent Convention
Art. 69 and its Protocol, Art. 123
Case law cited
NanoString v 10x Genomics, Court of Appeal, 26 February 2024, Court of Appeal, 13 May 2024 (UPC_CoA_1/2024), first-instance orders UPC_CFI_15/2023, UPC_CFI_114/2024 and UPC_CFI_452/2023

Related decisions

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: Application for a preliminary injunction, Order to preserve evidence (UPC), Supplementary protection certificate (SPC), Biosimilar medicinal product.

Dhenne Avocats blog: Pharmaceutical patents and the UPC: is the Court hostile to them?.

Publications by Matthieu Dhenne: The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Application for provisional measures
Outcome (Dhenne Avocats summary)
Les mesures provisoires demandées par Insulet contre EOFLOW sont refusées : la revendication 1 n'est probablement pas nouvelle au regard du document Roe, et les requêtes subsidiaires tardives sont irrecevables en référé.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 4 201 327
Fluid delivery device with transcutaneous access tool, insertion mechanism and blood glucose monitoring for use therewith
recorded proprietor: Insulet Corp
Mentioned in the analysis (role not qualified)
Also mentioned in 25 other decision(s): EOFLOW v Insulet (CFI, 22 July 2025) · EOFLOW v Insulet (CoA, 18 March 2026) · EOFlow v Insulet (CoA, 26 February 2026) · EOFlow v Insulet (CoA, 4 February 2026) · EOFlow v Insulet (CoA, 29 January 2026) · Herbert Smith Freehills Kramer (applicant) in Insulet v EOFLow (CoA, 2 · Insulet v EOFLOW (CFI, 15 October 2025) · EOFLOW v Insulet (CFI, ORD_26828/2025, 5 June 2025)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.